Karyopharm Therapeutics Inc (NASDAQ: KPTI) is a commercial-stage oncology company focused on the discovery, development, and commercialization of drugs that inhibit nuclear export. Revenue is generated primarily through net product sales of its approved therapies. The 10-K filed February 13, 2026 (accession 0001193125-26-049397) covers the fiscal year ended December 31, 2025. The filing excerpts provided do not contain sufficient detail to describe segment revenue percentages, specific product names, customer concentration, competitive positioning, geographic mix, founding year, or current leadership with confidence. Per the writing rules, unsupported facts are omitted. Additional filing content would be required to produce a fully grounded description meeting the 120 to 220 word target with specific financials, product names, and market context.

Source: SEC 10-K, filed 2026-02-13

Industry: Pharmaceutical Preparations Peers: Invivyd Inc Humacyte Inc Anika Therapeutics Inc Arcturus Therapeutics Holdings Inc Kalvista Pharmaceuticals Inc Eiger BioPharmaceuticals, Inc. Monte Rosa Therapeutics Inc Scholar Rock Holding Corp Vigil Neuroscience, Inc.